AKBA - Akebia Therapeutics, Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Recently reported position changes by institutional investors
Recent trades by U.S. Senators
No data for this ticker
Recent trades by U.S. Representatives
No data for this ticker
Quarterly net insider trading by a company's directors and management
Flights by private jets registered to AKBA
No data for this ticker
Federal grants, loans, and purchases. Click on a date for more info.
